Home > Articles > The NAD+ salvage pathway: how cells recycle NAD+
The NAD+ salvage pathway: how cells recycle NAD+
Prepared by: Research Desk
Prepared by: Research Desk. Sources are linked for verification.
Every cell is constantly spending NAD+. Enzymes such as PARPs, sirtuins and CD38 cleave it and release nicotinamide as a by-product. If cells had to rebuild NAD+ from scratch each time, the cost would be enormous. Instead, most of that nicotinamide is captured and turned back into NAD+. This loop is called the NAD salvage pathway. Reviews of NAD+ metabolism describe it as the main route that maintains NAD+ pools in mammalian tissues [1][2].
This explainer covers the enzymes in the loop and how salvage differs from the two other synthesis routes. It also covers why the loop matters for interpreting precursor research. For the wider picture of what NAD+ does, see our NAD+ guide.
Why NAD+ needs recycling at all
NAD+ has two roles. As an electron carrier it shuttles between NAD+ and NADH and is not destroyed. As an enzyme substrate it is destroyed: the ADP-ribose part is used, and nicotinamide (NAM) is released [1][3].
The main NAD+-consuming enzyme families named in the reviews are:
PARPs, which use NAD+ to build poly-ADP-ribose chains during DNA repair signalling.
Sirtuins, which remove acyl groups from proteins and release nicotinamide in the process.
CD38 and CD157, which are ectoenzymes with NAD+-glycohydrolase activity. CD38 is described as a major NAD+ consumer in tissues, especially with age and inflammation [3].
SARM1, an NAD+-cleaving enzyme studied mainly in nerve-cell degeneration [2].
Reviews describe NAD+ as having a rapid turnover in many tissues. The total pool can stay roughly stable while individual molecules are broken down and rebuilt many times over [3]. The salvage pathway makes that turnover sustainable.
The salvage pathway, step by step
The core loop has two enzymatic steps [1][2][4]:
Nicotinamide → NMN. The enzyme nicotinamide phosphoribosyltransferase (NAMPT) attaches a phosphoribose group, from PRPP, to nicotinamide. This produces nicotinamide mononucleotide (NMN). NAMPT is widely described as the rate-limiting step of mammalian salvage.
NMN → NAD+. NMN adenylyltransferases (NMNAT1, NMNAT2 and NMNAT3) add an AMP group from ATP, giving NAD+. The three isoforms are found in different compartments. NMNAT1 is mainly nuclear, NMNAT2 is associated with the Golgi and cytoplasm, and NMNAT3 has been linked to mitochondria [2][4].
Then NAD+ is consumed, nicotinamide is released, and the loop restarts.
Where nicotinamide riboside enters
Nicotinamide riboside (NR) joins the same loop by a side door. Nicotinamide riboside kinases (NRK1 and NRK2) phosphorylate NR directly to NMN, bypassing NAMPT. NMNAT enzymes then convert it to NAD+ [1][4]. This is why NR and NMN are often described as "salvage-pathway precursors": both converge on NMN.
How much of an oral precursor reaches tissues intact is a separate and debated question. Reviews note that NR and NMN can be broken down to nicotinamide before reaching cells [3]. Comparisons between precursors are covered in our NAD+ guide.
Feedback and limits
Because NAMPT sets the pace, its activity strongly shapes how fast NAD+ is regenerated. Reviews describe NAMPT as existing both inside cells (iNAMPT) and in an extracellular form (eNAMPT). They also describe its expression as varying with circadian timing and metabolic state [1][4]. Nicotinamide itself can also inhibit sirtuins at higher concentrations. This adds another layer of feedback within the loop [4].
How salvage differs from the other two routes
Mammalian cells have three recognised routes to NAD+ [2][4]:
Route | Starting molecule | Key enzymes | Main location noted in reviews |
|---|---|---|---|
De novo (kynurenine) pathway | Tryptophan | IDO/TDO, then a multi-step route to quinolinic acid; QPRT makes NaMN | Mainly liver (and kidney) |
Preiss-Handler pathway | Nicotinic acid (NA) | NAPRT makes NaMN; NMNAT makes NaAD; NAD synthetase (NADSYN) makes NAD+ | Liver, kidney, intestine |
Salvage pathway | Nicotinamide (and NR via NRK) | NAMPT, NRK1/2, NMNAT1-3 | Most tissues |
The de novo and Preiss-Handler routes merge at nicotinic acid mononucleotide (NaMN). From there they share the last two steps [2]. The salvage route differs because it never passes through the "acid" intermediates. It goes straight from NMN to NAD+.
The practical point in the reviews is about tissue distribution. Many tissues have limited capacity for the de novo route. They rely on recycling nicotinamide, or on NAD+ precursors and metabolites supplied by the liver through the circulation [3][4].
What studies report about the salvage loop
Most direct evidence about salvage enzymes comes from cell and animal studies. The human data are mostly measurements of NAD+ levels, not of pathway flux.
Human tissue and age. A study of human pelvic skin samples reported age-associated decreases in NAD+ and increases in markers of oxidative damage and PARP activity, with some associations differing by sex [5]. This is consistent with the idea that consumption can outpace supply. The study measured levels, not salvage-enzyme rates.
Senescent cells (cell and mouse study). Researchers reported that NAMPT and the NAD+ it supports governed the inflammatory secretory profile of senescent cells, often called the SASP [6]. In their models, raising NAD+ was associated with a stronger proinflammatory secretome. That result shows NAD+ supply can have context-dependent effects.
Intestinal inflammation (human tissue and mouse study). A study reported increased NAMPT expression in inflamed human intestinal tissue. In mouse models, blocking NAMPT reduced inflammation markers [7].
Lung fibrosis (mouse study). In bleomycin-exposed mice, investigators reported that NAMPT promoted fibrosis by driving macrophages toward an M2 phenotype [8].
NAMPT activity and aging measures (mouse study). A study in male mice reported that nicotine raised NAMPT activity and shifted NAD+ levels. It also reported changes in some aging-related measures [9]. This was an animal study of NAMPT biology. It provides no basis for human use of nicotine.
Taken together, these papers show that the salvage pathway is not simply "more is better". The same enzyme that keeps NAD+ supplied in healthy tissue is studied as a driver of inflammation and fibrosis in some disease models [6][7][8].
Human precursor trials and the salvage loop
Small randomized human trials have measured whether salvage-pathway precursors change NAD+ metabolites:
A randomized, placebo-controlled crossover trial of NR in healthy middle-aged and older adults reported that it was well tolerated. It also reported higher NAD+ in blood cells [10].
A randomized, placebo-controlled trial of NMN reported increased muscle insulin sensitivity, a physiological measure, in a small group of prediabetic women [11].
A 2026 PRISMA-guided systematic review collected preclinical and clinical studies of NAD+ supplementation. It is a useful map of which studies exist and how they were designed [12].
These trials measured NAD+ metabolites and selected physiological markers in small groups. They do not show which salvage step was rate-limiting in each participant, or how flux changed in specific tissues. For the regulatory status of these ingredients in the U.S., see our NMN, NR and IV NAD+ legal status page.
Measuring the salvage pathway: what a level can't tell you
A single NAD+ concentration is a snapshot of a pool that is being built and broken down at the same time. Reviews point out that steady-state levels do not show turnover. Two tissues with similar NAD+ levels could have very different synthesis and consumption rates [3]. Studying salvage directly needs methods that track flux, such as isotope-labelled precursors followed by mass spectrometry. Measuring enzyme expression or activity (NAMPT, NMNAT, CD38) is another approach. Blood-cell NAD+ measurements, which most human trials report, reflect circulating cells, not muscle, liver or brain [2][3].
This is the main reason our coverage separates "raised NAD+ in blood" from "changed NAD+ metabolism in a tissue". More on how pages are researched is in how this site works.
Further reading
The salvage pathway sits where enzymology, redox chemistry and metabolic regulation meet. Readers who want to go deeper than review articles often find a solid textbook the fastest way in. When comparing biochemistry and metabolism books, these criteria are the most useful:
Edition date. NAD+ biology has moved fast since the mid-2010s. Look for a recent edition that covers NAMPT, NRK enzymes, CD38 and SARM1, not only classic redox chemistry.
Pathway diagrams. The best texts draw the de novo, Preiss-Handler and salvage routes on one page, with enzyme names and cofactors shown.
Referencing. Chapters that cite primary literature let readers trace each claim, much as the sources list below does.
Level. Undergraduate textbooks explain mechanism clearly. Graduate-level or monograph-style books cover tissue compartments and flux in more depth.
Format and price transparency. Digital editions are searchable and often cheaper. Check whether a listed price is for a rental, a single chapter or the full text.
Pairing one general biochemistry textbook with one or two recent review articles, such as those in the sources below, gives both the fundamentals and the current research picture.
Frequently asked questions
Is the salvage pathway the main source of NAD+ in the body?
Reviews of NAD+ metabolism describe salvage from nicotinamide as the dominant route that maintains NAD+ pools in most mammalian tissues [1][2]. The de novo route from tryptophan is concentrated mainly in the liver and kidney [4].
What is the difference between NAMPT and NMNAT?
NAMPT converts nicotinamide into NMN and is considered the rate-limiting step of salvage. NMNAT enzymes (three isoforms in different cell compartments) convert NMN into NAD+ [2][4]. NR bypasses NAMPT through NRK enzymes but still needs NMNAT [1].
Does a higher NAD+ reading mean the salvage pathway is working faster?
Not necessarily. A measured NAD+ level reflects the balance between synthesis and consumption, not the speed of either [3]. Flux studies with labelled precursors are needed to separate the two.
Last updated: 19 October 2026.
Related on this site
NAD+ explained: biochemistry, precursors, testing and human evidence
NAD+ test buyer's guide: how at-home blood tests work and compare
Reading an NAD+ test report: units, sample types and reference ranges
NAD+ books: an evidence-graded reading list on sirtuins and aging
Nicotinamide riboside research: what human trials have measured
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.